Seattle, WA, Aug-14, 2018 — / Coherent Chronicle News / —
Alzheimer’s Drugs Market – Young Prospect for Aging Patient
The global Alzheimer’s drugs market was valued at US$ 7 billion in 2016 and is expected to witness a CAGR of 9.5% over the forecast period (2018- 2026).
Increasing aging population, improved diagnostics and development of novel drugs to drive growth of the Alzheimer’s drugs market. Increasing age is highest risk factor for Alzheimer’s disease, which is expected to propel demand for Alzheimer’s therapeutics. This is on account of increased life expectancy in global population, for instance according World Population Prospect report 2017, there is significant gains in life expectancy achieved globally in past decade, life expectancy at birth rose from approximately 67 to 71 years and all regions shared in the rise of life expectancy and in next several decades it would rise up to 78 years on average.
Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1373
As Alzheimer’s is most prevalent in age 65 year and above therefore increased life expectancy would face more patients with mild to moderate Alzheimer’s symptoms such as dementia. Europe currently has largest aged population above 60 years. Diagnostics prospect for Alzheimer’s disease also undergoing significant development, for instance AC immune along with Piramal healthcare developing Tau-PET imaging agent for better diagnosis of Alzheimer’s disease since 2014.
Key Vendors of Alzheimer’s Drugs Market: Key players operating in Alzheimer’s drugs market include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S and Teva Pharmaceuticals Industries Ltd., Other prominent players whose products are under clinical trials are Eli Lilly and Company, TauRx Pharmaceuticals Ltd, VTV Therapeutics, Hoffman-La Roche Ltd., AstraZeneca plc, and AC Immune.
The global Alzheimer’s drugs market is expected to exhibit a CAGR of 9.5% over the forecast period, owing to the presence of high potential market on account of aging population with increased life expectancy and rising awareness about disease in North America, Europe, and Asia Pacific.
Among different regions, North America holds largest share in Alzheimer’s drugs market, owing to high prevalence of Alzheimer’s disease and easy diagnosis and treatment access in region
Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1373
Alzheimer’s Drugs market report analyses the market potential for each geographical region based on the growth rate, macroeconomic parameters, consumer buying patterns, and market demand and supply scenarios.
Regions of Alzheimer’s Drugs market:
In the end, the report makes some important proposals for a new project of Alzheimer’s Drugs Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2016-2020 global Alzheimer’s Drugs industry covering all important parameters.
Alzheimer’s Drugs driver
Alzheimer’s Drugs challenge
Alzheimer’s Drugs trend
Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1373